Company Profile

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE3370.85-0.2 (-0.01 % )
PREV CLOSE (Rs.) 3371.05
OPEN PRICE (Rs.) 3375.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2565
TODAY'S LOW / HIGH (Rs.)3360.00 3395.00
52 WK LOW / HIGH (Rs.)3000 4970
NSE3369.50 -0.35 (-0.01 % )
PREV CLOSE(Rs.) 3369.85
OPEN PRICE (Rs.) 3369.00
BID PRICE (QTY) 3369.50 (44 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 11142
TODAY'S LOW / HIGH(Rs.) 3360.05 3394.00
52 WK LOW / HIGH (Rs.)3005 4970

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.06
TTM EPS (Rs.) 37.32
P/E Ratio 90.32
Book Value (Rs.) 181.83
Face Value (Rs.) 2
MCap (Rs. in Mn) 84271.25
Price/Earning (TTM) 74.29
Price/Sales (TTM) 10.36
Price/Book (MRQ) 18.54
PAT Margin (%) 11.47
ROCE (%) 31.24
Incorporation Year : 1979

Management Info :

Narayan K Seshadri - Chairman Gagandeep Singh Bedi - Managing Director

Registered Office :

Address : Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone : 080 6774 8000

Registrar's Details : Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE, MCX
NEWS More
01Jun06-01-2021$ Termination Of Distribution Agreement Between Astrazeneca Pharma India Limited And Abbott Healthcare Private Limited Termination Of Distribution
We refer to our announcement of December 7, 2018, wherein we had informed about the Distribution Agreement entered into between AstraZeneca Pharma India Limited (AstraZeneca India) and Abbott Healthcare Private Limited (Abbott) for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Under the said agreement, Abbott promoted and distributed Dapagliflozin under the brand name 'Gledepa' and the combination of Dapagliflozin with Metformin under the brand name 'Gledepa Met'. Please note that by virtue of the said Distribution Agreement, Abbott had not been conferred with any license to the patents over the drugs comprising Dapagliflozin, and the license granted to Abbott was with respect only to the use of the trademarks 'Gledepa' and 'Gledepa Met' We now wish to further update that AstraZeneca India and Abbott have mutually terminated the Distribution Agreement on 27th May 2021. Copy of complete intimation is enclosed for reference.
We refer to our announcement of December 7, 2018, wherein we ha..
28May05-28-2021$AstraZeneca Pharma, Abbott Healthcare terminate distribution agreement AstraZeneca Pharma, Abbott H

AstraZeneca Pharma and Abbott Healthcare have mutually terminated the distribution agreement on May 27, 2021. AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively. Earlier, the Distribution agreement had entered into between AstraZeneca Pharma India and Abbott Healthcare (Abbott) for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

AstraZeneca Pharma and Abbott Healthcare have mutually terminat..
26May05-26-2021$ Reappointment Of Statutory Auditors For Second Term Reappointment Of Statutory
The Board of Directors of the Company at their meeting held on May 25, 2021, have, inter alia, approved the Re-appointment of M/s. Price Waterhouse & Co. Chartered Accountants LLP (ICAI Firm Registration No.304026E/E-300009), as the Statutory Auditors of the Company for a second term of five (5) years, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM), to hold office from the conclusion of 42nd AGM till the conclusion of 47th AGM. The Company has received the certificate of eligibility in accordance with Sections 139, 141 and other applicable provisions, if any of the Companies Act, 2013 read with the Rules issued thereunder, from M/s. Price Waterhouse & Co. Chartered Accountants LLP.
The Board of Directors of the Company at their meeting held on..
19May05-19-2021$ Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday, May 25, 2021 Board Meeting Intimation fo
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, May 25, 2021 inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from March 16, 2021 to May 27, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting..
19May05-19-2021$Astrazeneca Pharma India informs about board meeting Astrazeneca Pharma India inf
Astrazeneca Pharma India has informed that a meeting of the Board of Directors of AstraZeneca Pharma India will be held on Tuesday, May 25, 2021, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. The Company further informed that the ‘Trading Window’ remains closed for all Designated Persons, from March 16, 2021 to May 27, 2021 in terms of AstraZeneca Pharma India - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

The above information is a part of company’s filings submitted to BSE.
Astrazeneca Pharma India has informed that a meeting of the Boa..
Financials More
Rs. in Millions
QTR Mar 21 ANNUAL 21
Net Profit272.78933.039999999999
Gross Profit 368.38 1270.94
Operating Profit 429.621483.13
Net Sales 2102.578135.63
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 19086.15 (4.92%)
M.Cap ( in Cr)
40556.74
Sanofi India (BSE)
 8367.90 (3.43%)
M.Cap ( in Cr)
19271.79
Alkem Laboratories (BSE)
 3454.55 (3.70%)
M.Cap ( in Cr)
41304.33
Sun Pharma Inds. (BSE)
 774.00 (10.06%)
M.Cap ( in Cr)
185708.53
Divi's Lab (BSE)
 4904.65 (1.20%)
M.Cap ( in Cr)
130203.05
Shareholding Pattern More
PROMOTERS 75 %
NON-INSTITUTION 21.56 %
MUTUAL FUNDS/UTI 0.94 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes